Login to Your Account

Cubicin Positive In Phase III Against Two New Infections

By Randall Osborne

Wednesday, June 29, 2005
Cubist Pharmaceuticals Inc. said its Phase III trial with Cubicin (daptomycin) hit its primary endpoints against Staphylococcus aureus endocarditis and bacteremia, and the company has a supplementary new drug application in the works. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription